Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683028 | 0.86 | ADRB2 (0.49) | ADRB2ADRB1 | |
| SCHEMBL2818621 | 0.81 | ADRB2 (0.49) | ADRB2ADRB1 | |
| SCHEMBL2815878 | 0.81 | ADRB2 (0.50) | ADRB2ADRB1 | |
| SCHEMBL13225819 | 0.80 | ADRB2 (0.36) | ADRB2ADRB1 | |
| SCHEMBL2213239 | 0.78 | ADRB2 (0.49) | ADRB2ADRB1 | |
| SCHEMBL3178715 | 0.78 | ADRB2 (0.51) | ADRB2ADRB1 | |
| SCHEMBL2214988 | 0.77 | ADRB2 (0.50) | ADRB2ADRB1 | |
| SCHEMBL2816287 | 0.76 | ADRB2 (0.52) | ADRB2ADRB1 | |
| SCHEMBL3595006 | 0.76 | ADRB2 (0.62) | ADRB2ADRB1 | |
| SCHEMBL2213182 | 0.76 | ADRB2 (0.47) | ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249200-A1 | Novel Compounds 569 | ASTRAZENECA AB (SE) | 2010-09-30 | — | — | US | disclosed |
| US-20100144606-A1 | COMBINATION 408 | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-7709511-B2 | Benzothiazolone derivatives | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-7700782-B2 | Compounds 569 | ASTRAZENECA AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-20100022491-A1 | 4-HYDROXY-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOL-7YL COMPOUNDS FOR MODULATION OF B2-ADRENORECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2010-01-28 | — | — | US | disclosed |
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| US-20080207698-A1 | Novel Compounds 569 | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| EP-1915354-A1 | NOVEL BENZOTHIAZOLONE DERIVATIVES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007018461-A1 | NOVEL BENZOTHIAZOLONE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144606-A1 | COMBINATION 408 | NR3C2, PTGER2, LTB4R2 | ADRB2 51/4885ADRB1 37/4885 |
| US-20080207698-A1 | Novel Compounds 569 | RB1, CNKSR1, CDK9 | ADRB2 1549/4885ADRB1 788/4885 |
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | NR0B1, RB1, CCND1 | ADRB2 156/4885ADRB1 29/4885 |
| US-20100022491-A1 | 4-HYDROXY-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOL-7YL COMPOUNDS FOR MODULATION OF B2-ADRENORECEPTOR ACTIVITY | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885 |
| US-20100249200-A1 | Novel Compounds 569 | RB1, CNKSR1, CDK9 | ADRB2 1549/4885ADRB1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.